Ring Closing Metathesis Mediated Synthesis of 4a-Aryloxodecahydroisoquinolines, Intermediates in the Preparation of Novel Opiates

Spiros Liras,^{*,1} Martin P. Allen,¹ and James F. Blake²

Pfizer Global Research and Development, Groton, Connecticut 06340

spiros_liras@groton.pfizer.com

Received August 15, 2001

ORGANIC LETTERS 2001 Vol. 3, No. 22

3483-3486

ABSTRACT



The concise syntheses of the 4a-aryldecahydroisoquinolines 1 and 2 through a uniform strategy starting from *N*-methyl-3-allyl-4-piperidinone are reported in this Letter. Key transformations include a ring closing metathesis reaction to prepare a *trans*-octahydroisoquinoline common intermediate and a regiocontrolled hydroboration–oxidation sequence.

The 4a-aryldecahydroisoquinolines **1** and **2** (Scheme 1)represent structural fragments of morphine with significant pharmacological activity. The compounds exhibit potent affinity for the μ opioid receptor and possess antinociceptive properties consistent with those of μ receptor agonists.³ The pharmaceutical importance of these compounds is further enhanced by their utility as advanced intermediates for the synthesis of novel selective ligands for the δ opioid receptor.⁴ Synthetic efforts toward the 4a-aryldecahydroisoquinoline **1** have been previously reported.⁵ In contrast, the synthesis of compound **2** has been the subject of fewer reports.⁶ As part of a program that aimed at the design and synthesis of novel δ opioid receptor ligands, we sought to develop concise syntheses for substrates **1** and **2**. In this Letter we report a uniform approach to the targeted 4a-aryldecahydroisoquino-lines through common intermediates highlighted by a ring closing metathesis reaction and a regiochemically controlled hydroboration—oxidation step.



⁽¹⁾ CNS medicinal chemistry.

⁽²⁾ Exploratory Medicinal Sciences, computational chemistry.

⁽³⁾ For a review of the opioid ligands, see: Casy, A. F.; Parfitt, R. T. *Opioid Analgesics: Chemistry and Receptors*; Plenum Press: New York, 1986.

⁽⁴⁾ For recent examples, see: (a) Dondio, G.; Ronzoni, S.; Eggleston, D. S.; Artico, M.; Petrillo, P.; Petrone, G.; Visentin, L.; Farina, C.; Vecchietti, V.; Clarke, G. D. *J. Med. Chem.* **1997**, *40*, 3192. (b) Nagase, H.; Kawai, K.; Hayakawa, J.; Wakita, H.; Mizusuna, A.; Matsuura, H.; Tajima, C.; Takezawa, Y.; Endoh, T. *Chem. Pharm. Bull.* **1998**, *46*(11), 1695.



For the syntheses of both substrates, we envisioned an approach as described in Scheme 2. The diallyl piperidine **8**, precursor to the ring closing metathesis reaction, would be accessed following an allylation reaction of the metalloenamine generated from compound **5**. A ring closing metathesis of compound **8** would furnish a *trans* octahydroisoquinoline with a quaternary carbon center, which after a regioselective hydroboration—oxidation sequence would be converted to the target compounds **1** and **2**. The regiochemical preference of the hydroboration—oxidation step could be predicted on the basis of molecular orbital calculations.

The reduction of this plan to practice commenced with the multigram preparation of 3-allyl-N-methyl-4-piperidinone **3** according to literature procedures.⁷ Related piperidinones have been converted to the 3-alkyl-4-aryltetrahydropyridines similar to 5 via aryl Grignard or aryllithium additions followed by regioselective dehydration.⁸ As an alternative to this strategy, we envisioned the preparation of compound 5 from a precursor vinyl triflate utilizing organopalladium chemistry (Scheme 3). Thus, the piperidinone 3 was transformed with exclusive regiocontrol to the vinyl triflate 4 in 92% yield with LiHMDS and N-phenyl triflamide9 in THF at -78 °C. The vinyl triflate was converted to the desired tetrahydropyridine 5 after Suzuki coupling with the commercially available 3-methoxyphenylboronic acid. The yields for the Suzuki coupling ranged from 48% to 94%. Optimum reaction conditions for this step were discovered when the vinyl triflate and boronic acid were treated with KBr, K₃-PO₄, and Pd(PPh₃)₄ as catalyst in dioxane solvent at 85 °C to afford compound 5 in 94% yield.¹⁰ With tetrahydropyridine 5 available, our attention was turned to the formation of diallylpiperidine 7. The preparation of diallylpiperidine 7 was achieved via a metalloenamine generation-alkylation sequence. This sequence was first reported in the context of



^{*a*} (a) LiHMDS, *N*-phenyltrifluoromethanesulfonimide, THF -78 °C to rt, 92%; (b) 3-methoxyphenylboronic acid, KBr, K₃PO₄, Pd(PPh₃)₄, 1,4-dioxane, 85 °C, 94%; (c) sec-Buli, allyl bromide, THF, -45 °C to -78 °C to rt; (d) NaBH₄, MeOH, rt, 88% for steps c and d; (e) ACE-Cl, 1,2-dichloroethane, reflux, then methanol, reflux; (f) di-*tert*-butyl dicarbonate, Et₃N, dichloromethane, rt, 80% for steps e and f.

the synthesis of related morphinoid alkaloids.¹¹ In the event, treatment of compound **5** with sec-BuLi in THF at -45 °C followed by addition of allyl bromide produced enamine **6** in quantitative yield. The crude enamine was reduced with NaBH₄ in methanol to afford piperidine **7** in 88% yield for the two steps. The *N*-methylpiperidine was subsequently converted to the *N*-Boc equivalent to ultimately produce a compound with an easily removable nitrogen-protecting group, suitable for analogue formation. Thus, after treatment of **7** with 1-chloroethyl chloroformate in dichloroethane at reflux, subsequent carbamate methanolysis and treatment of the crude hydrochloride salt with di-*tert*-butyl dicarbonate and triethylamine compound **8** was obtained in 80% overall yield.

With the synthesis of diallylpiperidines **7** and **8** completed, our attention was turned to the ring closing metathesis transformation (Scheme 4). The diallylpiperidine **8** was converted to the cyclic olefin **11** after treatment with 0.1 equiv of the Grubbs catalyst **9** in dichloroethane at 60 °C in 93% yield. Similarly, the hydrochloride salt of compound **7** was converted to the corresponding olefin **10** in 88% yield.¹²

The regioselective functionalization of the olefin in compound **11** was predicted on the basis of molecular orbital interactions. Restricted Hartree–Fock calculations were carried out for the transition states corresponding to

^{(5) (}a) Weller, D.; Gless, R. D.; Rapoport, H. J. Org. Chem. 1977, 42, 1485. (b) Cantrell, B. E.; Paschal, J. W.; Zimmerman, D. M. J. Org. Chem. 1989, 54, 1442. (c) Judd, D. B.; Brown, D. S.; Lloyd, J. E.; McElroy, A. B.; Scopes, D. I. C.; Birch, P. J.; Hayes, A. G.; Sheehan, M. J. J. Med. Chem. 1992, 35, 48.

⁽⁶⁾ See ref 5c.

⁽⁷⁾ Bell, K. H.; Portoghese, P. S. J. Med. Chem. 1973, 16, 203.

^{(8) (}a) Barnett, C. J.; Copley-Merriman, C. R.; Maki, J. J. Org. Chem. **1989**, 54, 4795. (b) Werner, J. A.; Cerbone, L. R.; Frank, S. A.; Ward, J. A.; Labib, P.; Tharp-Taylor, R. W.; Ryan, C. W. J. Org. Chem. **1996**, 61, 587.

⁽⁹⁾ McMurry, J. E.; Scott, W. J. Tetrahedron Lett. 1983, 24, 979.

⁽¹⁰⁾ For a review, see: Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457.

⁽¹¹⁾ Evans, D. A.; Mitch, C. H.; Thomas, R. C.; Zimmerman, D. M.; Robey, R. L. J. Am. Chem. Soc. **1980**, 102, 5955.



^{*a*} (a) Grubbs catalyst **9**, 1,2-dichloroethane, 60 °C, 93% for compound **11**, 88% for compound **10**; (b) 9-BBN, THF, reflux, 30% aqueous H_2O_2 , EtOH, 6 N NaOH, quantitative yield for **12** and **13** (3:1 ratio); (c) TPAP, NMO, dichloromethane, rt, 88% for **1** and 84% for **2**; (d) HCl, EtOAc, rt, 85%.

the hydroboration of **11** with both 9-BBN and borane. The geometries for this series of molecules were fully optimized by means of analytical energy gradients¹³ with the 6-31G-(d)-basis set¹⁴ in the gas phase. The ab initio molecular orbital calculations were carried out with the Gaussian 94 series of programs on a Silicon Graphics computer.¹⁵ Comparison of the transition state energies for the reaction of **11** with 9-BBN shows a preference for product **12** over **13** of 0.616 kcal/mol, corresponding to a ratio of 2.83:1. The reaction of **11** with borane is predicted to favor the regioisomer, **13**, by 0.767 kcal/mol (predicted ratio 1:3.65). Our findings are consistent with prior ab initio calculations that implicate

(14) Francl, M. M.; Pietro, W. J.; Hehre, W. J.; Binkley, J. S.; Gordon, M. S.; DeFrees, D. J.; Pople, J. J. Chem. Phys. **1982**, 77, 3654.



both steric and electronic factors in the regioselectivity.¹⁶ Experimental results supported the computational chemistry predictions. Thus, treatment of olefin **11** with a sterically hindered borane such as 9-BBN in refluxing THF, followed by oxidation of the organoborane species, yielded in quantitative yield a 3:1 ratio of the separable, isomeric alcohols 12 and 13. Conversely, treatment of 11 with the smaller borane-dimethyl sulfide reagent complex yielded a 3:1 ratio of alcohols 13 and 12 in a not optimized 52% yield. The final step for the preparation of isoquinolines 1 and 2 was the oxidation of the secondary hydroxyl groups. Typically, Swern oxidation reactions had been employed for this transformation in good yields. In this instance, oxidation of alcohols 12 and 13 with TPAP and N-morpholine oxide afforded ketones 1 and 2 in 88% and 84% yields, respectively.

The stereochemistry of the major product **12** was confirmed from a crystal structure obtained from its hydrochloride salt **14** (Figure 1). Compound **14** was produced after removal of the nitrogen-protecting group with HCl in ethyl acetate at room temperature in 85% yield.

In conclusion, the efficient syntheses of the 4a-aryldecahydroisoquinolines **1** and **2** through a uniform strategy were reported in this Letter. The desired compounds exhibit significant pharmacological activity at opioid receptors and provide useful intermediates for the synthesis of novel and selective δ opioid receptor ligands. Key synthetic steps in this approach include a highly efficient ring closing metathesis reaction to form a *trans* octahydroisoquinoline substrate and a regioselective hydroboration—oxidation reaction sequence.

⁽¹²⁾ For recent reviews regarding applications of the ring closing metathesis reaction, see: (a) Grubbs, R. H.; Miller, S. J.; Fu, G. C. Acc. Chem. Res. **1995**, 28, 446. (b) Pandit, U. K.; Overkleeft, H. S.; Borer, B. C.; Bieraugel, H. Eur. J. Org. Chem. **1999**, 5, 959. (c) Wright, D. L. Curr. Org. Chem. **1999**, 3, 211. (d) Phillips, A. J.; Abell, A. D. Aldrichimica Acta **1999**, 32, 75. (e) Maier, M. E. Angew. Chem., Int. Ed. **2000**, 39, 2073.

⁽¹³⁾ Schlegel, H. B. J. Comput. Chem. 1982, 3, 214.

⁽¹⁵⁾ Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Gill, P. M. W.; Johnson, B. G.; Robb, M. A.; Cheeseman, J. R.; Keith, T.; Petersson, G. A.; Montgomery, J. A.; Raghavachari, K.; Al-Laham, M. A.; Zakrzewski, V. G.; Ortiz, J. V.; Foresman, J. B.; Peng, C. Y.; Ayala, P. Y.; Chen, W.; Wong, M. W.; Andres, J. L.; Replogle, E. S.; Gomperts, R.; Martin, L.; Fox, D. J.; Binkley, J. S.; DeFrees, D. J.; Baker, J.; Stewart, J. P.; Head-Gordon, M.; Gonzalez, C.; Pople, J. A. *Gaussian 94 Revision B.3*; Gaussian, Inc.: Pittsburgh, PA, 1995.

⁽¹⁶⁾ Wang, X.; Li, Y.; Wu, Y. D.; Paddon-Row, M. N.; Rondan, N. G.; Houk, K. N. J. Org. Chem. **1990**, 55, 2601.

Acknowledgment. The authors thank Dr. Jon Bordner, small molecule crystallography, Pfizer Global Research and Development, Groton Laboratories, for the X-ray structure of compound 14 and Ms. Sharon Mellow for preparation of the document.

Supporting Information Available: Representative experimental procedures for the preparation of compounds **4**, **5**, **7**, **8**, **11**, **12**, **13**, **1**, and **2**. This material is available free of charge via the Internet at http://pubs.acs.org. OL016588B